\
&
Contact us
\
&
Contact us
Published on | 5 years ago
Programmes FET ICT NMBP SPACE SME Instrument Health Food Energy Transport Climate/Environment Societies Security EIC Pilot Batteries Circular Industries Horizon 2020The EIT Community is responding with concrete activities and resources to support the global response to the pandemic and with solutions powered by innovators and organisations within its ecosystem. The EIT therefore launched the EIT Crisis Response Initiative as part of the EU’s collective efforts to tackle the COVID-19 crisis.
The EIT Governing Board decided to mobilise EUR 60 million of additional funding to innovators powering high-impact solutions that tackle this unprecedented social and economic challenge. The financing will allow the launch of new innovation projects to address the immediate crisis as part of the ‘Pandemic Response Projects’, and will support highly innovative start-ups, scale-ups and SMEs crucial to the economy’s fast recovery to benefit from additional funding under the ‘Venture Support Instrument’.
More info on these activitites per Knowledge and Innovation Communities (KICs) on this page
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
